2-methyl-1-(2-methyl-1H-indol-3-yl)propan-1-one | 29957-84-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-methyl-1-(2-methyl-1H-indol-3-yl)propan-1-one
• 英文别名: 3-iso-Butyroyl-2-methylindol；3-Isobutyryl-2-methylindol；2-methyl-1-(2-methyl-indol-3-yl)-propan-1-one；2-Methyl-1-(2-methyl-indol-3-yl)-propan-1-on；3-Isobutyryl-2-methylindole
• CAS: 29957-84-4
• 化学式: C₁₃H₁₅NO
• 分子量: 201.268
• InChiKey: WWDQTCMEUQMLKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-methyl-1-(2-methyl-1H-indol-3-yl)propan-1-one 在 phenyltrimethylammonium tribromide 作用下， 以 四氢呋喃 为溶剂， 以75 %的产率得到2-bromo-2-methyl-1-(2-methyl-1H-indol-3-yl)propan-1-one
  参考文献：
  名称：

  通过光诱导 Pd 催化丁二烯 1,2-双官能化实现吲哚的催化不对称级联脱芳构化

  摘要：

  在此，公开了通过光诱导Pd催化1,3-丁二烯的1,2-双碳官能化的吲哚级联不对称脱芳构化反应。该过程产生了结构新颖的手性螺吲哚，具有两个连续的立体中心，具有高非对映体比率（高达 >20 : 1 dr）和良好到优异的对映体比率（高达 97 : 3 er）。

  DOI：

  10.1002/anie.202404388
• 作为产物：
  描述：

  2-甲基吲哚 、 异丁酰氯 在 氯化二乙基铝 作用下， 以 正己烷 、 二氯甲烷 为溶剂， 反应 4.5h， 以77%的产率得到2-methyl-1-(2-methyl-1H-indol-3-yl)propan-1-one
  参考文献：
  名称：

  金催化3-酰基吲哚/炔的脱酰基环异构反应：咔唑合成的新方法

  摘要：

  描述了通过金催化的3-丙烯腈/炔的脱酰基环异构化来合成官能化咔唑的方法。提出了一种针对这些转化的机制建议，其中涉及一种新的羰基基团，可在失去酰基离子中间体后促进杂化断裂。消除的胞嘧啶离子种类可以被有机金中间体捕获，得到酰基咔唑。

  DOI：

  10.1021/ol2012154

文献信息

• Gold-Catalyzed Deacylative Cycloisomerization Reactions of 3-Acylindole/ynes: A New Approach for Carbazole Synthesis
  作者：Lu Wang、Guijie Li、Yuanhong Liu

  DOI：10.1021/ol2012154

  日期：2011.8.5

  The synthesis of functionalized carbazoles through gold-catalyzed deacylative cycloisomerization of 3-acylindole/ynes is described. A mechanistic proposal for these transformations involving a novel carbonyl group facilitated heterolytic fragmentation upon the loss of an acylium ion intermediate is presented. The eliminated acylium ion species could be trapped by the organogold intermediate to afford

  描述了通过金催化的3-丙烯腈/炔的脱酰基环异构化来合成官能化咔唑的方法。提出了一种针对这些转化的机制建议，其中涉及一种新的羰基基团，可在失去酰基离子中间体后促进杂化断裂。消除的胞嘧啶离子种类可以被有机金中间体捕获，得到酰基咔唑。
• [EN] PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO<br/>[FR] ANTAGONISTES DU RÉCEPTEUR EP2 DE LA PROSTAGLANDINE, DÉRIVÉS, ET UTILISATIONS ASSOCIÉS
  申请人：UNIV EMORY

  公开号：WO2020191208A1

  公开（公告）日：2020-09-24

  The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, epilepsy, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.

  该公开涉及前列腺素受体EP2拮抗剂、衍生物、组合物以及相关方法。在某些实施方式中，该公开涉及治疗或预防EP2受体激活在生理角色中发挥作用的疾病和情况的方法，例如但不限于脑损伤、炎症性疾病、癫痫、癫痫后的神经炎症、疼痛、子宫内膜异位症、癌症、类风湿性关节炎、皮肤炎症、血管炎症、结肠炎和神经系统疾病，通过向需要的受试者施用含有本文所披露的化合物的药物组合物。
• Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity
  作者：Elena De Vita、Peter Schüler、Scott Lovell、Jasmin Lohbeck、Sven Kullmann、Eitan Rabinovich、Amiram Sananes、Bernd Heßling、Veronique Hamon、Niv Papo、Jochen Hess、Edward W. Tate、Nikolas Gunkel、Aubry K. Miller

  DOI：10.1021/acs.jmedchem.8b01106

  日期：2018.10.11

  Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease that belongs to the family of tissue kallikreins (KLKs). Many KLKs are investigated as potential biomarkers for cancer as well as therapeutic drug targets for a number of pathologies. KLK6, in particular, has been implicated in neurodegenerative diseases and cancer, but target validation has been hampered by a lack of selective inhibitors. This work introduces a class of depsipeptidic KLK6 inhibitors, discovered via high-throughput screening, which were found to function as substrate mimics that transiently acylate the catalytic serine of KLK6. Detailed structure-activity relationship studies, aided by in silico modeling, uncovered strict structural requirements for potency, stability, and acyl-enzyme complex half-life. An optimized scaffold, DKFZ-251, demonstrated good selectivity for KLK6 compared to other KLKs, and on-target activity in a cellular assay. Moreover, DKFZ-633, an inhibitor-derived activity based probe, could be used to pull down active endogenous KLK6.
• Alberti, Gazzetta Chimica Italiana, 1957, vol. 87, p. 720,724
  作者：Alberti

  DOI：——

  日期：——
• BERGMAN J.; BAECKVALL J. E., TETRAHEDRON <TETR-AB>, 1975, 31, NO 17, 2063-2073
  作者：BERGMAN J.、 BAECKVALL J. E.

  DOI：——

  日期：——